Astrazeneca reckons a bispecific approach can unlock the potential of CTLA-4 inhibition, and is to start a large phase II programme this year.
Tirzepatide’s clinical programme is set to double in size when a huge head-to-head outcome study gets under way. Costs will balloon too.
Almost in stealth mode the Swiss firm moves to begin a huge pivotal programme rivalling that of the IDO and IL-2 mechanisms.
Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.
If its study of lung denervation hits, Nuvaira could get US approval and maybe swing a trade sale.
Alcohol kills – and in this case, that could be a good thing.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.